|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.80/2.24
|
企业价值
1.56B
|
资产负债 |
每股账面净值
10.68
|
现金流量 |
现金流量率
0.13
|
损益表 |
收益
310.46M
|
每股收益
4.64
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/23 22:28 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. |